All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Camidanlumab Tesirine Plus Pembrolizumab Produces Responses But Increases Immune Toxicities in Select Solid Tumors

January 9th 2024

Camidanlumab tesirine was well tolerated as a monotherapy and elicited responses when given with pembrolizumab in patients with advanced solid tumors.

CRISPR-Based Anti-CD19 CAR T-Cell Therapy Is Safe and Effective in Relapsed/Refractory NHL

January 9th 2024

BRL-201 had a manageable safety profile and elicited early indications of efficacy in patients with relapsed/refractory non-Hodgkin lymphoma.

Cancer Researcher Thomas Martin Receives $4.6 million CIRM Grant

January 9th 2024

Thomas G. Martin, MD, has received a grant from the California Institute of Regenerative Medicine to produce a CAR T cell therapy for multiple myeloma.

FDA Grants Priority Review to Tisotumab Vedotin sBLA for Recurrent or Metastatic Cervical Cancer

January 9th 2024

The FDA has granted priority review to a sBLA seeking to convert the accelerated approval of tisotumab vedotin to full approval in select patients with cervical cancer.

FDA Issues CRL to Zolbetuximab for Advanced HER2–, CLDN18.2+ Gastric/GEJ Cancer

January 9th 2024

The FDA has issued a CRL to the zolbetuximab BLA for patients with HER2- gastric or GEJ junction adenocarcinoma whose tumors are Claudin18.2 positive.

Combination Regimens Stir Excitement in Advanced RCC

January 9th 2024

Expert oncologists who treat patients with advanced renal cell carcinoma discuss updates from clinical trials presented during the 2023 ESMO Congress.

2023 Yields Several Promising Trial Updates in dMMR/pMMR Endometrial Cancer

January 9th 2024

Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.

NMPA Approval Sought for Frontline Cadonilimab Plus Chemo in Gastric or GEJ Adenocarcinoma

January 8th 2024

China’s NMPA has accepted the sNDA seeking the approval of cadonilimab plus chemotherapy for use in select patients with gastric or GEJ adenocarcinomas.

Sequencing BCMA-Directed Therapies Expands Multiple Myeloma Treatment Horizons

January 8th 2024

Sikander Ailawadhi, MD, spotlights the characteristics of multiple myeloma that drive the decision to use teclistamab-cqyv, elranatamab-bcmm, or talquetamab-tgvs.

Asciminib Provides MMR Benefits vs SOC TKIs in Newly Diagnosed Ph+ CML

January 8th 2024

Asciminib demonstrated a favorable safety profile and induced statistically significant and clinically meaningful major molecular response benefits vs standard-of-care TKIs in patients with newly diagnosed, Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase.

FDA Grants Fast Track Status to Rinatabart Sesutecan for FRα-Expressing Ovarian Cancer

January 8th 2024

The FDA has granted fast track designation to rinatabart sesutecan for the treatment of patients with FRα-expressing high-grade serous or endometrioid platinum-resistant ovarian cancer.

Florida Cancer Specialists & Research Institute Promotes Members of Executive and Physician Leadership

January 8th 2024

Florida Cancer Specialists & Research Institute, LLC announced the promotion of two members of its executive and physician leadership team.

Iopofosine I 131 Generates Efficacy Signals in Waldenström Macroglobulinemia

January 8th 2024

Iopofosine I 131 monotherapy elicited durable responses and was associated with a tolerable safety profile in patients with heavily pretreated, multi-class refractory Waldenström macroglobulinemia.

Effects of Chemotherapy and Other Anticancer Agent Shortages Linger

January 8th 2024

Although the severity of the shortage of chemotherapy agents, particularly with the platinum-based therapies cisplatin and carboplatin, has receded from the heights seen earlier in 2023, clinicians are still dealing with its ramifications and having to strategically manage how they employ certain chemotherapies.

Practical Toxicity Management Awareness With FGFR Inhibitors Improves Real-World Patient Outcomes

January 8th 2024

Vivek Subbiah, MD, emphasizes the need for improved guidance on practical toxicity management for various FGFR-altered malignancies, highlights best practices for monitoring and managing the most common on-target toxicities associated with FGFR inhibitors, and discusses the key implications of this review for those utilizing FGFR inhibitors.

Fox Chase Cancer Center’s Zoe Landau Wins Best Professional Poster Award From International Cancer Education Conference

January 7th 2024

Zoe Landau, MPH, Project Manager in the lab of Linda Fleisher, PhD, MPH, was recently recognized with the Best Professional Poster Award at the 2023 International Cancer Education Conference for her work detailing the mychoice digital health tool.

Optimal Personalization of Therapy In TNBC Necessitates Consistent Biomarker Identification

January 7th 2024

Pooja Advani, MBBS, MD, details the encouraging activity of antibody-drug conjugates in triple-negative breast cancer, the importance of utilizing next-generation sequencing to inform treatment selection after progression on CDK4/6 inhibitors in this disease setting, and more.

Sylvester Cancer Researcher and Technology Innovator Named Fellow of the National Academy of Inventors

January 6th 2024

Shanta Dhar, PhD, assistant director of Technology and Innovation at Sylvester Comprehensive Cancer Center, has been named a fellow of the National Academy of Inventors.

A Journey Across the Atlantic Leads to a Path in Surgical Oncology

January 6th 2024

A planned 5-year trip in the United States coupled with a thirst for knowledge turned into a lifetime of surgical oncology accomplishments for Eleftherios “Terry” Mamounas, MD, MPH.

Neoadjuvant SBRT Plus Cemiplimab Results in Pathologic Responses in Resectable HCC

January 5th 2024

Significant tumor necrosis greater than 70% occurred in 3 patients with resectable hepatocellular carcinoma following neoadjuvant treatment with low-dose stereotactic body radiation therapy and cemiplimab-rwlc and adjuvant cemiplimab.